Research programme: small interfering RNA therapeutics - Lipoxen

Drug Profile

Research programme: small interfering RNA therapeutics - Lipoxen

Alternative Names: siRNA - Lipoxen; siRNAblate technology - Lipoxen

Latest Information Update: 15 Sep 2011

Price : $50

At a glance

  • Originator Lipoxen Technologies; Unknown
  • Developer Unknown; Xenetic Biosciences
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 03 Jun 2011 Discontinued - Preclinical for Undefined indication in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top